Type 1 Papillary Renal Cell Carcinoma Completed Phase 2 Trials for Tivantinib (DB12200)

Also known as: Papillary Renal Cell Carcinoma Type 1

DBCOND0029157 (Type 1 Papillary Renal Cell Carcinoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01688973Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by SurgeryTreatment